CNTB beat EPS expectations by 74.98%
Aug 19, 2025, 10:36 AM
0.00%
What does CNTB do
Connect Biopharma Holdings, based in San Diego, develops therapies for T cell-driven inflammatory diseases and went public on March 19, 2021. Its lead candidates include rademikibart for atopic dermatitis and asthma, and icanbelimod for ulcerative colitis.
Connect Biopharma Holdings (CNTB) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Connect Biopharma Holdings's actual EPS was -$0.23, beating the estimate of -$0.92 per share, resulting in a 74.98% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.